troglitazone has been researched along with Retinal Neovascularization in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murata, T | 1 |
| Hata, Y | 1 |
| Ishibashi, T | 1 |
| Kim, S | 1 |
| Hsueh, WA | 1 |
| Law, RE | 1 |
| Hinton, DR | 1 |
1 other study available for troglitazone and Retinal Neovascularization
| Article | Year |
|---|---|
Response of experimental retinal neovascularization to thiazolidinediones.
Topics: Animals; Blotting, Western; Cattle; Cell Division; Cell Movement; Chromans; Endothelial Growth Facto | 2001 |